Related Experiment Video

Updated: Jun 9, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Use of statins in patients with chronic hepatitis C

Miranda R Andrus1, Jessica East

  • 1Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Huntsville, AL, USA.

Southern Medical Journal
|September 7, 2010
PubMed

Insights

Hepatitis C patients with stable liver disease may benefit from statins to reduce cardiovascular risk. Current guidelines contraindicate statins for active liver disease, but evidence suggests safety in stable cases.

Area of Science:

  • Hepatology
  • Cardiology
  • Clinical Pharmacology

Background:

  • Hepatitis C is a significant cause of liver failure and a public health concern.
  • Hepatitis C patients face increased cardiovascular disease (CVD) risk, making statins potentially beneficial.
  • National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) guidelines contraindicate statins in active or chronic liver disease.

Purpose of the Study:

  • To evaluate the safety and efficacy of statin therapy in patients with Hepatitis C.
  • To review existing literature on statin use in Hepatitis C patients and assess cardiovascular risk reduction.

Main Methods:

  • Literature review of studies examining statin use in Hepatitis C patients.
  • Analysis of safety data, including aminotransferase levels and hepatotoxicity, in patients with and without Hepatitis C who received statins.

Main Results:

  • Limited literature suggests no clinically significant differences in aminotransferase elevations or hepatotoxicity between Hepatitis C patients on statins and those not.
  • Statins are not recommended for advanced end-stage liver disease due to lack of safety data and compromised drug metabolism.

Conclusions:

  • Statins can be considered for patients with chronic, stable Hepatitis C who have elevated cardiac risk or a history of cardiac events.
  • Continued avoidance of statins is advised for advanced end-stage liver disease due to safety concerns and impaired drug metabolism.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: